RSS   Newsletter   Contact   Advertise with us
Post Online Media

Juno Therapeutics appoints Rupert Vessey to board

Juno TherapeuticsJuno Therapeutics, a biopharmaceutical company, announced it has appointed Rupert Vessey to its board of directors.

Before joining Celgene in January 2015, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck and had numerous roles of increasing responsibility at GlaxoSmithKline.

Article continues below

READ MORE Juno Therapeutics names Robert Azelby as chief commercial officer

Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM BCh), and Molecular Immunology (DPhil).

He is an elected Fellow of the Royal College of Physicians.


More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy